Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation Study

被引：0
|
作者：
Yao, J. [1 ]
Chan, J. [2 ]
Mita, A. [3 ]
Kundu, M. [4 ]
Valera, S. Z. [4 ]
Unge, P. [5 ]
Strosberg, J. [6 ]
Wolin, E. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Pharma AG, Basel, Switzerland
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
NEUROENDOCRINOLOGY | 2016年 / 103卷
关键词：
Pasireotide; MTD;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K8
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [1] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    [J]. PANCREAS, 2017, 46 (03) : 437 - 437
  • [2] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Phase I dose-escalation study of pasireotide LAR in patients with advanced neuroendocrine tumors.
    Phan, Alexandria T.
    Wolin, Edward M.
    Chan, Jennifer A.
    Huang, Jerry M.
    Hudson, Michelle
    Hughes, Gareth
    Shen, Guoxiang
    Strosberg, Jonathan R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    [J]. CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [5] Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
    Yao, James C.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan G.
    Resendiz, Karina Hermosillo
    Hu, Ke
    Ravichandran, Shoba
    Strosberg, Jonathan R.
    Wolin, Edward M.
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 3177 - 3186
  • [6] Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia
    Huetter, Marie-Luise
    Fiedler, Walter
    Kuendgen, Andrea
    Krauter, Juergen
    von Lilienfeld-Toal, Marie
    Kayser, Sabine
    Rafler, Heidi
    Doehner, Hartmut
    Schlenk, Richard F.
    [J]. BLOOD, 2010, 116 (21) : 1350 - 1351
  • [7] Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.
    Tolcher, Anthony W.
    Victoria, Ivan
    Germann, Nathalie
    Luecke, Stephan
    Bailey, Mark
    Kordes, Maximilian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study
    Huinink, Wim W. ten Bokkel
    Sufliarsky, Jozef
    Smit, Willem M.
    Spanik, Stanislav
    Wagnerova, Maria
    Hirte, Hal W.
    Kaye, Stan
    Johri, Anandhi R.
    Oza, Amit M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3097 - 3103
  • [9] SQ3370-001 IS A MULTI-CENTER OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO TEST A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO TREAT ADVANCED SOLID TUMORS
    Bhadri, Vivek
    Bui, Nam
    Guminski, Alexander
    Oneto, Jose Mejia
    Murthy, Ravi
    Sankhala, Kamalesh
    Saville, M. Wayne
    Srinivasan, Sangeetha
    Steffner, Robert
    Subbiah, Vivek
    Wang, Ding
    Yee, Nathan
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A253 - A254
  • [10] Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
    Gutierrez, M. E.
    Giaccone, G.
    Liu, S. V.
    Rajan, A.
    Guha, U.
    Halfdanarson, T. R.
    Curtis, K. K.
    Kunz, P. L.
    Gabrail, N.
    Hinson, J. M.
    Orlemans, E. O.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345